AbbVie

News

AbbVie upscales Voyager alliance with new target, more cash

AbbVie has extended its collaboration with gene therapy specialist Voyager Therapeutics, adding a new programme in Parkinson’s disease and another $1.5 billion in potential fees.

Views & Analysis

Market access roundup: UK HTA shakeups as Brexit fears deepe...

With a Brexit deal still out of sight, there have been intensified warnings in the UK about potential disruptions to medicine supplies that could follow a no-deal scenario.

News

Patients switch to lower dose of Pfizer's RA pill after safe...

Pfizer is moving rheumatoid arthritis patients to a lower dose of its blockbuster inflammatory diseases pill Xeljanz in a clinical study, after a safety signal emerged in the trial of patie

News

AbbVie’s JAK inhibitor upadacitinib gets Priority Review

AbbVie’s attempts to diversify beyond Humira have been boosted as its investigational drug upadacitinib has been granted Priority Review by the FDA for moder

News

AbbVie and J&J claim new Imbruvica okay in US

AbbVie and Johnson & Johnson’s Imbruvica has become the first chemo-free treatment for first-line chronic lymphocytic leukaemia (CLL) to be approved by the FDA, its tenth indication.

News

AbbVie wobbles as biosimilars bite Humira

AbbVie’s shares slipped ahead of the weekend when its fourth-quarter revenues missed forecasts, after biosimilar competition – particularly in Europe – weakened cash cow product Humira.

AbbVie upscales Voyager alliance with new target, more cash

Market access roundup: UK HTA shakeups as Brexit fears deepe...

Patients switch to lower dose of Pfizer's RA pill after safe...

AbbVie’s JAK inhibitor upadacitinib gets Priority Review

AbbVie and J&J claim new Imbruvica okay in US

AbbVie wobbles as biosimilars bite Humira

The long-delayed promise of the microbiome, with Sam Possemi...

How to meet your physicians where they are online

AbbVie

Editor's Picks